These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32054324)

  • 1. Pharmacogenetics in primary care.
    Dawes M
    Healthc Manage Forum; 2020 May; 33(3):97-101. PubMed ID: 32054324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
    Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
    Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
    Deverka PA; McLeod HL
    Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Chalkidou K; Rawlins M
    Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
    Weitzel KW; Duong BQ; Arwood MJ; Owusu-Obeng A; Abul-Husn NS; Bernhardt BA; Decker B; Denny JC; Dietrich E; Gums J; Madden EB; Pollin TI; Wu RR; Haga SB; Horowitz CR
    Pharmacogenomics; 2019 Oct; 20(15):1103-1112. PubMed ID: 31588877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.
    Bousman C; Maruf AA; Müller DJ
    Curr Opin Psychiatry; 2019 Jan; 32(1):7-15. PubMed ID: 30299306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression.
    Herbild L; Bech M; Gyrd-Hansen D
    Value Health; 2009 Jun; 12(4):560-7. PubMed ID: 18980634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the opportunity for pharmacogenetic intervention in primary care.
    Grice GR; Seaton TL; Woodland AM; McLeod HL
    Pharmacogenomics; 2006 Jan; 7(1):61-5. PubMed ID: 16354125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetic considerations in the elderly patient.
    Bright DR; Calinski DM; Kisor DF
    Consult Pharm; 2015 Apr; 30(4):228-39. PubMed ID: 25893701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
    Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
    Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].
    Stingl JC; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1509-21. PubMed ID: 24170080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
    Bradley P; Shiekh M; Mehra V; Vrbicky K; Layle S; Olson MC; Maciel A; Cullors A; Garces JA; Lukowiak AA
    J Psychiatr Res; 2018 Jan; 96():100-107. PubMed ID: 28992526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
    Verhoef TI; Redekop WK; de Boer A; Maitland-van der Zee AH;
    Pharmacogenomics; 2015 Jan; 16(2):101-14. PubMed ID: 25616097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
    Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
    World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.
    Gillis NK; Patel JN; Innocenti F
    Clin Pharmacol Ther; 2014 Mar; 95(3):269-80. PubMed ID: 24136381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance.
    Brazell C; Freeman A; Mosteller M
    Br J Clin Pharmacol; 2002 Mar; 53(3):224-31. PubMed ID: 11874384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.
    Olgiati P; Bajo E; Bigelli M; De Ronchi D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):147-54. PubMed ID: 21911028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.
    Friede K; Li J; Voora D
    Clin Chem; 2017 Jan; 63(1):177-185. PubMed ID: 27864383
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.